NCT04628767 2026-03-18
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
Clinical Trials
18 trialsNCT07063745 2026-03-17
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT01810913 2026-03-13
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT07106762 2026-03-10
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07129993 2026-03-05
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Recruiting
NCT07100080 2026-03-03
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06236438 2026-02-23
LIVIGNO-4
AbbVie
Phase 2/3 Recruiting
NCT06225596 2026-02-17
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2/3 Recruiting
NCT06783140 2025-12-05
PLATINUM-CAN
University Health Network, Toronto
Phase 2/3 Recruiting
NCT05893888 2025-06-15
Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma
Privo Technologies
Phase 2/3 Recruiting
NCT06214572 2025-04-11
RUGB
Tata Memorial Centre
Phase 2/3 Recruiting
NCT06493552 2025-04-03
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Phase 2/3 Recruiting
NCT06037980 2025-02-17
PURITY
Gruppo Oncologico del Nord-Ovest
Phase 2/3 Recruiting
NCT05255653 2024-11-29
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT06288373 2024-10-30
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital
Phase 2/3 Recruiting
NCT06138028 2024-07-24
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Qingdao Central Hospital
Phase 2/3 Recruiting
NCT05057130 2024-04-01
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Blokhin's Russian Cancer Research Center
Phase 2/3 Recruiting
NCT05125055 2023-11-22
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Shanghai Jiao Tong University School of Medicine
Phase 2/3 Recruiting